Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5) (JiVitA-5)
Primary Purpose
Birth Weight, Miscarriage, Small-for-gestational Age
Status
Terminated
Phase
Not Applicable
Locations
Bangladesh
Study Type
Interventional
Intervention
Multiple micronutrient supplement
Placebo Oral Tablet
Sponsored by
About this trial
This is an interventional prevention trial for Birth Weight focused on measuring preconceptional multiple micronutrient supplementation, periconceptional multiple micronutrient supplementation, pregnancy outcomes, adolescent pregnancy, Bangladesh
Eligibility Criteria
Inclusion Criteria:
- Resident of 566 rural sectors (clusters) in Gaibandha district
- Recently-married woman
- Nulligravid
Exclusion Criteria:
- Women with a history of previous pregnancy
- Women who refuse consent for participation
Sites / Locations
- JiVitA Project Office
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Multiple micronutrient supplement
Placebo
Arm Description
Daily micronutrient supplement
Daily identifcal placebo tablet
Outcomes
Primary Outcome Measures
Preterm Birth - number of live-births occurring earlier than 37 weeks gestation among all live-births (with known gestational age)
Pregnancies ending in a live birth less than 37 weeks' gestation
Miscarriage - number of spontaneous abortions occurring earlier than 24 weeks gestation among all pregnancies (with known gestational age)
Pregnancies ending as a spontaneous abortion less than 24 weeks' gestation
Small for Gestational Age - number of live-born neonates weighing less than the 10th centile of birth weight for gestational age and sex among all live-births (with known gestational age and birth weight)
Infants weighing less than the 10th centile of birth weight for gestational age and sex
Low Birth Weight - number of live-born neonates weighing less than 2500 g at birth among all live-births (with known birth weight)
Infants weighing less than 2500 g at birth
Secondary Outcome Measures
Anemia in Pregnant Women
Hemoglobin in whole blood, less than a cutoff of 110 g/L
Iron Status
Distribution of plasma ferritin, ng/mL
Vitamin A Status
Distribution of plasma retinol, micromoles/L
Vitamin E Status
Distribution of plasma alpha-tocopherol, micromoles/L
Folate Status
Distribution of total plasma folate, nmol/L
Vitamin B12 Status
Distribution of total plasma cobalamin, pmol/L
Selenium Status
Distribution of total plasma selenium, ng/mL
Full Information
NCT ID
NCT03921177
First Posted
April 11, 2019
Last Updated
June 1, 2021
Sponsor
Johns Hopkins Bloomberg School of Public Health
Collaborators
JiVitA Project, Gaibandha, Bangladesh
1. Study Identification
Unique Protocol Identification Number
NCT03921177
Brief Title
Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5)
Acronym
JiVitA-5
Official Title
Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Terminated
Why Stopped
Extended COVID-19 restrictions on field research and limited funding
Study Start Date
January 17, 2019 (Actual)
Primary Completion Date
November 30, 2020 (Actual)
Study Completion Date
May 29, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins Bloomberg School of Public Health
Collaborators
JiVitA Project, Gaibandha, Bangladesh
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this cluster-randomized trial is to evaluate the efficacy of daily, multiple micronutrient (MM) supplement versus identical placebo use among nulligravid, recently married women, starting preconceptionally through the 1st trimester of pregnancy, in reducing low birth weight and other adverse pregnancy outcomes in rural Bangladesh.
Detailed Description
Micronutrient deficiencies are common among women of reproductive age in rural South Asia, including Bangladesh. Antenatal multiple micronutrient (MM) supplementation, usually starting toward the end of the 1st trimester, has been shown to reduce low birth weight in many cultures. In northern Bangladesh, where the current study will be conducted, MM versus iron-folic acid supplementation has been shown to extend gestational age, thereby reducing risks of preterm birth 15% and low birth weight by 12%, and reduce risk of stillbirth by 11% (West KP et al. JAMA 2014), and to reduce risk of micronutrient deficiencies (Schulze KJ et al J Nutr 2019). Since it is plausible that women of reproductive age conceive in a state of lower micronutrient nutriture, it remains unknown the degree to which MM supplementation, starting preconceptionally through the 1st trimester (covering the periconceptional and embryonic period) can benefit pregnancy outcome. Further, there is concern that newlywed, nulligravid women in rural South Asia are at high risk, and may be at particular health and pregnancy risks due to micronutrient deficiencies resulting from dietary inadequacy.
The investigators propose to conduct a double-masked, cluster-randomized, placebo-controlled trial among recently married women in 18 rural unions of Gaibandha District, Bangladesh, that will provide a daily tablet containing either (a) a MM formulation containing a US Institute of Medicine (IOM) Recommended Dietary Allowance (RDA) for pregnancy for 15 essential vitamins and minerals (and closely approximates the UNIMAP formula), or (b) a placebo tablet of identical appearance containing no micronutrients, during a period extending from at least one-month prior to last menstrual period through the 1st trimester of pregnancy (~12 weeks' gestation). The study area will comprise 566 rural clusters (sectors) each with 250-400 households, serving as units of randomization. Consenting, recently married women will be detected through routine community surveillance and start to receive coded, double-masked supplements, resupplied during monthly home visits. Participating women will receive coded supplements for daily consumption until the end of the trial or until determined to be pregnant. On detection of pregnancy by a history of amenorrhea confirmed by urine test, irrespective of randomized allocation, all women will be switched to receive an open-labeled MM supplement, expected to occur toward the end of the 1st trimester, which will continue through 3 months post-partum. This switch is in response to previous positive effects shown on pregnancy outcomes with a MM supplement starting at the end of the 1st trimester.
Participating married women will be periodically interviewed for socioeconomic, morbidity, dietary and lifestyle risk factors and assessed by anthropometry. Pregnancies will be followed for miscarriage, abortion, live birth and still birth outcomes. Newborn anthropometry will be assessed to determine birth weight and size. Infants and mothers will be eligible for additional breast feeding, dietary, morbidity and growth assessments at 8 days, and 1, 3 and 6 months after delivery. Participating women resident in a predefined subset of the study area (n~68 sectors) will receive enhanced assessments, including blood draw in the end of the 1st trimester for subsequent laboratory assessment of micronutrient status, and body composition, among other measures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Birth Weight, Miscarriage, Small-for-gestational Age, Preterm Birth
Keywords
preconceptional multiple micronutrient supplementation, periconceptional multiple micronutrient supplementation, pregnancy outcomes, adolescent pregnancy, Bangladesh
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Cluster-randomized, placebo-controlled concurrent intervention trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Multiple micronutrient and placebo tablets are identical in size, shape, and appearance; coding of supplements carried out independent of investigators and research team.
Allocation
Randomized
Enrollment
9859 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Multiple micronutrient supplement
Arm Type
Experimental
Arm Description
Daily micronutrient supplement
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Daily identifcal placebo tablet
Intervention Type
Dietary Supplement
Intervention Name(s)
Multiple micronutrient supplement
Intervention Description
Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
Intervention Type
Drug
Intervention Name(s)
Placebo Oral Tablet
Intervention Description
Preconception to 12-weeks gestation: identical tablet
Primary Outcome Measure Information:
Title
Preterm Birth - number of live-births occurring earlier than 37 weeks gestation among all live-births (with known gestational age)
Description
Pregnancies ending in a live birth less than 37 weeks' gestation
Time Frame
up to 38 weeks of gestation
Title
Miscarriage - number of spontaneous abortions occurring earlier than 24 weeks gestation among all pregnancies (with known gestational age)
Description
Pregnancies ending as a spontaneous abortion less than 24 weeks' gestation
Time Frame
up to 24 weeks gestation
Title
Small for Gestational Age - number of live-born neonates weighing less than the 10th centile of birth weight for gestational age and sex among all live-births (with known gestational age and birth weight)
Description
Infants weighing less than the 10th centile of birth weight for gestational age and sex
Time Frame
up to 72 hours after live birth
Title
Low Birth Weight - number of live-born neonates weighing less than 2500 g at birth among all live-births (with known birth weight)
Description
Infants weighing less than 2500 g at birth
Time Frame
Measured from time of live birth through 72 hours after birth
Secondary Outcome Measure Information:
Title
Anemia in Pregnant Women
Description
Hemoglobin in whole blood, less than a cutoff of 110 g/L
Time Frame
Measured at 12 weeks gestation
Title
Iron Status
Description
Distribution of plasma ferritin, ng/mL
Time Frame
Measured at 12 weeks gestation
Title
Vitamin A Status
Description
Distribution of plasma retinol, micromoles/L
Time Frame
Measured at 12 weeks gestation
Title
Vitamin E Status
Description
Distribution of plasma alpha-tocopherol, micromoles/L
Time Frame
Measured at 12 weeks gestation
Title
Folate Status
Description
Distribution of total plasma folate, nmol/L
Time Frame
Measured at 12 weeks gestation
Title
Vitamin B12 Status
Description
Distribution of total plasma cobalamin, pmol/L
Time Frame
Measured at 12 weeks gestation
Title
Selenium Status
Description
Distribution of total plasma selenium, ng/mL
Time Frame
Measured at 12 weeks gestation
10. Eligibility
Sex
Female
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Resident of 566 rural sectors (clusters) in Gaibandha district
Recently-married woman
Nulligravid
Exclusion Criteria:
Women with a history of previous pregnancy
Women who refuse consent for participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Keith P West, Jr., DrPH
Organizational Affiliation
Johns Hopkins Bloomberg School of Public Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
JiVitA Project Office
City
Gaibandha
State/Province
Gaibandha Distict
ZIP/Postal Code
5700
Country
Bangladesh
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
To be delineated
IPD Sharing Time Frame
Not later than 4 years after completion of data collection in the field
IPD Sharing Access Criteria
To be delineated
Citations:
PubMed Identifier
25536256
Citation
West KP Jr, Shamim AA, Mehra S, Labrique AB, Ali H, Shaikh S, Klemm RD, Wu LS, Mitra M, Haque R, Hanif AA, Massie AB, Merrill RD, Schulze KJ, Christian P. Effect of maternal multiple micronutrient vs iron-folic acid supplementation on infant mortality and adverse birth outcomes in rural Bangladesh: the JiVitA-3 randomized trial. JAMA. 2014 Dec 24-31;312(24):2649-58. doi: 10.1001/jama.2014.16819.
Results Reference
background
PubMed Identifier
18402187
Citation
Sugimoto JD, Labrique AB, Ahmad S, Rashid M, Klemm RD, Christian P, West KP Jr. Development and management of a geographic information system for health research in a developing-country setting: a case study from Bangladesh. J Health Popul Nutr. 2007 Dec;25(4):436-47.
Results Reference
background
PubMed Identifier
27032981
Citation
Gernand AD, Schulze KJ, Stewart CP, West KP Jr, Christian P. Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. Nat Rev Endocrinol. 2016 May;12(5):274-89. doi: 10.1038/nrendo.2016.37. Epub 2016 Apr 1.
Results Reference
background
PubMed Identifier
21510905
Citation
Labrique AB, Christian P, Klemm RD, Rashid M, Shamim AA, Massie A, Schulze K, Hackman A, West KP Jr. A cluster-randomized, placebo-controlled, maternal vitamin A or beta-carotene supplementation trial in Bangladesh: design and methods. Trials. 2011 Apr 21;12:102. doi: 10.1186/1745-6215-12-102.
Results Reference
background
Learn more about this trial
Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5)
We'll reach out to this number within 24 hrs